

MT2021-26: Ruxolitinib for Early Lung Dysfunction after HSCT: a Phase II Study

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 5 to 60 years old - undergone allogeneic HCT and experiencing respiratory difficulty - if able to become pregnant or father a child, must use two highly effective methods of birth control for 90 days after the last dose of study drug - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- active uncontrolled pulmonary infection - women who are pregnant or breast feeding - treated with investigational agent for GVHD within the 30 days prior to first dose of study treatment

Conditions & Interventions

Conditions:

Cancer

Keywords:

GVHD, Hematopoietic Stem Cell Transplant, HSCT, Lung, Respiratory

More Information

Description: While hematopoietic stem cell transplant (HSCT) is an effective therapy, as many as 25% of patients develop problems with their lungs as a result of this treatment. Bronchiolitis obliterans (BO) is a type of lung injury after HSCT due to graft versus host disease. BO is commonly diagnosed late in patients, when lung injury is hard to treat and can be irreversible, leading to long-term lung disease or even death. The purpose of this research is to learn more about ruxolitinib as an early treatment for lung injury and BO after HSCT. Patients who are diagnosed with early lung dysfunction will be eligible for this research study.

Study Contact: Samuel Goldfarb - goldf091@umn.edu

Principal Investigator: Samuel Goldfarb

Phase: PHASE2

IRB

Number: STUDY00014986

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.